A federal judge in Maryland has sentenced Nader Z. Pourhassan, the former chief executive officer of biotechnology company CytoDyn, to 30 months in federal prison for securities fraud, wire fraud, and insider trading in a case that included key ties to Germantown, Maryland’s biotech sector.
Pourhassan, 62, was convicted of misleading investors about the development and regulatory status of CytoDyn’s experimental drug, while secretly selling millions of shares of company stock for personal gain. Prosecutors said his actions generated more than $4 million in illicit profits and artificially inflated the company’s stock price.
The sentencing was handed down in the U.S. District Court for the District of Maryland, where the case drew attention in part because of the involvement of Amarex Clinical Research, a Germantown-based contract research organization that worked closely with CytoDyn on clinical trials and communications with the U.S. Food and Drug Administration.
Germantown’s Role in the Case
According to court records, Amarex Clinical Research, headquartered in Germantown, was responsible for managing clinical trials and regulatory submissions related to CytoDyn’s drug candidate. Federal prosecutors said misleading statements about trial results and regulatory progress were central to the fraud scheme.
Former Amarex CEO Kazem Kazempour was originally convicted alongside Pourhassan. However, a Maryland federal judge later vacated some of Kazempour’s convictions and granted him a new trial, citing concerns that the jury may have been influenced by evidence specific to Pourhassan.
The Germantown connection placed a local spotlight on the case, highlighting the important role Montgomery County plays in the national biotech and clinical research industry — and the scrutiny that comes with it.
Sentencing Details
In addition to the prison sentence, the court ordered Pourhassan to forfeit more than $4.4 million and pay over $5.3 million in restitution to investors harmed by the fraud.
Prosecutors emphasized that the scheme took place during a time of heightened public interest in biotech companies, particularly those claiming progress in treatments related to infectious diseases. They said accountability was necessary to protect investors and public trust.
Broader Impact
CytoDyn, based in Washington state, gained widespread attention for its development of leronlimab, a monoclonal antibody studied for HIV and later COVID-19. Federal authorities concluded that investors were repeatedly misled about the drug’s prospects, forming the basis for the convictions.
The case underscores the national significance of Maryland’s biotech corridor, including Germantown, while serving as a reminder that executives and research partners alike are subject to federal oversight when public companies and investor funds are involved.
